key: cord-0735703-smix1qk8
authors: Attia, Abdallah S.; Hussein, Mohammad; Aboueisha, Mohamed A.; Omar, Mahmoud; Youssef, Mohanad R.; Mankowski, Nicholas; Miller, Michael; Munshi, Ruhul; Swinford, Aubrey; Kline, Adam; Nguyen, Therese; Toraih, Eman; Duchesne, Juan; Kandil, Emad
title: Altered mental status is a predictor of poor outcomes in COVID-19 patients: A cohort study
date: 2021-10-05
journal: PLoS One
DOI: 10.1371/journal.pone.0258095
sha: c1c46b5d799644fb65b737dcb24d4a4f69636f6b
doc_id: 735703
cord_uid: smix1qk8

INTRODUCTION: Several studies have described typical clinical manifestations, including fever, cough, diarrhea, and fatigue with COVID-19 infection. However, there are limited data on the association between the presence of neurological manifestations on hospital admission, disease severity, and outcomes. We sought to investigate this correlation to help understand the disease burden. METHODS: We delivered a multi-center retrospective study of positive laboratory-confirmed COVID-19 patients. Clinical presentation, laboratory values, complications, and outcomes data were reported. Our findings of interest were Intensive Care Unit (ICU) admission, intubation, mechanical ventilation, and in-hospital mortality. RESULTS: A total of 502 patients with a mean age of 60.83 ± 15.5 years, of them 71 patients (14.14%) presented with altered mental status, these patients showed higher odds of ICU admission (OR = 2.06, 95%CI = 1.18 to 3.59, p = 0.01), mechanical ventilation (OR = 3.28, 95%CI = 1.86 to 5.78, p < 0.001), prolonged (>4 days) mechanical ventilation (OR = 4.35, 95%CI = 1.89 to 10, p = 0.001), acute kidney injury (OR = 2.18, 95%CI = 1.28 to 3.74, p = 0.004), and mortality (HR = 2.82, 95%CI = 1.49 to 5.29, p = 0.01). CONCLUSION: This cohort study found that neurological presentations are associated with higher odds of adverse events. When examining patients with neurological manifestations, clinicians should suspect COVID-19 to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

Since the Spanish flu pandemic in 1918, humankind hasn't encountered such an overwhelming health crisis created by the novel 2019 coronavirus disease (COVID-19) pandemic [1] . As of August 2, 2020, the World Health Organization (WHO) reports that 680,894 people have died around the world, spanning different countries, ethnicities, religions, and socioeconomic class. Furthermore, the Emergency Committee on COVID-19 unanimously admitted that the outbreak still poses a public health emergency of international concern [2] .

COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was initially thought to primarily infect the respiratory system with dyspnea, cough, expectoration, and chest pain being common presenting symptoms [3] . However, as the pandemic continues, it is has been shown that the virus affects a wide range of organ systems, including the gastrointestinal, hepatic, renal, and cardiovascular systems. Well-documented extrapulmonary findings in COVID-19 patients include diarrhea, nausea, vomiting, elevated liver enzymes, kidney dysfunction, elevated troponin and CK-MB, systolic dysfunction, and heart failure, especially those who developed a severe and critical illness [3] [4] [5] [6] [7] [8] [9] .

Some articles have illustrated symptoms suggestive of potential nervous system involvement with many studies demonstrating anosmia, ageusia, dizziness, seizure, altered mental status (AMS), myalgia, headache, syncope, somnolence, and coma in COVID-19 patients [7] [8] [9] 10] . Neuropsychiatric manifestations, such as anxiety, depression, insomnia, and psychosis, are reported as well [7, 10] . Case reports and case series have reported para-infectious conditions including Guillain-Barre syndrome and ataxia [11] . However, there is limited data available describing neurological symptoms as presenting manifestations among COVID-19 patients. The purpose of this multi-center retrospective cohort study was to investigate whether presenting with neurological symptoms is a predictor of poor health outcomes and adverse events in COVID-19 positive patients.

This is a multi-center retrospective cohort study that was performed after acquiring Tulane University Institutional Review Board (IRB) approval. The patient data were collected on COVID-19 confirmed positive patients, who were admitted from March 20, 2020, to May 10, 2020, to Tulane Medical Center (TMC) and University Medical Center (UMC) in New Orleans, LA. The patient data was collected using Research Electronic Data Capture (REDCap) hosted at Tulane University Medical School. REDCap is a secure, web-based software platform designed to support data capture for research studies, providing an intuitive interface for validated data capture and audit trails for tracking data manipulation and export procedures [12] . Patients were divided into two groups: with and without altered mental status (AMS) which encompasses confusion, amnesia, loss of alertness, disorientation, defects in judgment or thought, unusual or strange behavior, poor regulation of emotions, and disruptions in perception, psychomotor skills, and behavior. Patients were diagnosed with AMS on admission by the attending physician and patients were not on any sedative agents at the time of diagnosis.

Demographics, presenting symptoms, comorbidities, clinical notes, laboratory values, and health outcomes were extracted from the electronic medical records using a standardized data collection. Patient orientation and mental state were determined using Glasgow Coma Scale (GCS), patients with decreased GCS were considered to have Altered mental status. The severity of the disease was determined by two scoring systems: CURB-65 and Quick Sequential Organ Failure Assessment (qSOFA). The CURB-65 score is based on the presence of confusion, blood urea nitrogen level >19 mg/dL (>7 mmol/L), respiratory rate �30, blood pressure (systolic <90 mmHg or diastolic �60 mmHg), and age �65 years [13] . (2) The qSOFA score is based on a GCS <15, respiratory rate �22, and systolic blood pressure �100 [14] .

A comparison between patients with and without AMS was performed. Outcome measures investigated included disease course, Intensive Care Unit (ICU) admission, intubation, unplanned reintubation, mechanical ventilation, duration of mechanical ventilation, prolonged mechanical ventilation, ARDS, bacteremia, sepsis, acute kidney injury, length of hospital stay, and mortality.

Data management was performed using SAS v9.4, while SPSS v26.0 was used for statistical analysis. Chi-square and Fisher's Exact tests were applied for categorical variables. Student's t and Mann-Whitney U tests were used for continuous variables. The two-sided p-value was set to be significant at <0.05. Multiple regression analysis was iterated using binary logistic regression models for all outcomes and cox hazard proportionate regression model for survival, adjusted by age, sex, obesity, and neuropsychiatric comorbidity.

We included a total of 502 COVID-19 confirmed positive patients with a mean age of 60.83 ± 15.5 years, and 238 patients (47.4%) were males. Their mean body mass index (BMI) was 33 

Patients presented with AMS showed worse outcomes compared to patients without AMS. Presenting with AMS was associated with higher rates of ICU admission (42.3% versus 27.7%, p = 0.017), intubation (45.1% versus 27%, p = 0.003), mechanical ventilation (47.9% versus 24.6%, p < 0.001), unplanned reintubation (35.3% versus 9.5%, p = 0.012), sepsis (23.9% versus 13.5%, p = 0.03), and acute kidney injury (N = 26, 36.6% versus N = 90, 20.9%, p = 0.006), Table 2 .

Patients presented with AMS had a higher rate of mortality (29.6% versus 11.6%, p < 0.001), earlier death (9.05 ± 5.08 days versus 15.07 ± 9.27, p = 0.007), and longer duration on ventilators (4.63 ± 6.08 days versus 1.43 ± 3.51 days, p < 0.001), Table 2 .

The multiple regression analysis was adjusted for age, sex, obesity, and neuropsychiatric comorbidities. This analysis revealed that patients presented with AMS had higher odds of 

The COVID-19 pandemic has been a serious health emergency and has caused an unprecedented international disaster while creating damaging social, economic, and political consequences that will likely have devastating long-term effects. Following disease-control guidelines, identifying risk factors, and recognizing different manifestations of COVID-19 infection is critical to deterring the spread and progression to severe disease. In response to this crisis, we conducted a retrospective cohort study on 502 hospitalized laboratory-confirmed COVID-19 patients to identify the outcomes associated with neurological symptoms, specifically AMS. Angiotensin-converting enzyme 2 (ACE2) is the host functional receptor recognized by viral protein (spike) and allows the SARS-CoV-2 to enter the cell [15] . It is documented that SARS-CoV-2 has a higher affinity for ACE2 compared to its predecessor, SARS-CoV, explaining the higher rates of transmission. Due to the high presence of ACE2 on type II alveolar epithelial cells, the lung is the primary target and most vulnerable organ. However, the expression of ACE2 is ubiquitous, presenting in other multiple human tissues, including adipose tissue and nervous system [7, [16] [17] [18] . Due to increased expression in ACE2 in adipose tissue, obese individuals, could develop an explosive systemic inflammatory response, possibly contributing to the development of a more severe form of the disease [19] . Expression of ACE2 on glial cells, neurons, and capillary endothelial cells suggests that SARS-CoV-2 may invade the central nervous system (CNS) via direct invasion or cerebrovascular endothelium [7, [20] [21] [22] .

Paniz-Mondolfi et al. reported the presence of SARS-CoV-2 in brain tissue from the postmortem examination of a COVID-19 patient by implementing a transmission electron microscope. The viral particles were detected in the frontal lobe and matched the structural characteristics of SARS-CoV-2. Notably, these viral particles were found in the small vesicles of endothelial cells, which supports CNS invasion via hematogenous pathways may be a cause of the rapid progression of neurological symptoms [23] . Additionally, SARS-CoV-2 was identified in the cerebrospinal fluid (CSF) via polymerase chain reaction (PCR) in a male patient suffering from impaired consciousness and transient generalized seizures, with typical meningitis and encephalitis characteristics shown on the magnetic resonance imaging (MRI). Interestingly, this case presented with negative PCR results in the nasopharyngeal swab, which indicated that CNS invasion might have occurred in the early phase of COVID-19 infection [24] . It is also suggested that direct invasion into the neuronal cells and retrograde transport from the olfactory bulb may be the pathophysiology of anosmia experienced by some COVID-19 patients [22, 25] .

To our knowledge, this is the first cohort study comparing outcomes between COVID-19 patients with and without neurologic symptoms, specifically AMS, while utilizing validated scoring systems (GCS, CURB-65, and qSOFA). Our initial univariate analysis showed that 14.14% of the COVID-19 patients presented to the hospital with AMS. These patients had higher rates of developing adverse events such as ICU admission, intubation, mechanical ventilation, prolonged ventilation, extended hospital stay, and mortality. But they had a lower rate of shortness of breath which could be explained due to the decreased reporting of symptoms with patients with AMS [26] . Out of the patients presenting with AMS in our cohort, 25 (35.2%) presented with no other symptoms. Mao et al. also reported that neurological symptoms, including impaired consciousness, occurred early in the disease course, sometimes preceding typical respiratory symptoms [7] . This suggests that neurological symptoms, such as AMS, may be signs of impending clinical decline in the early stages of COVID-19.

The patients with AMS presented with comparatively more severe disease, shown by the significantly higher CURB-65 and qSOFA scores at the time of admission. Additionally, patients with AMS presented with significantly higher neutrophil-to-lymphocyte ratio and CRP, which are risk factors of poor health outcomes and possible predictors of severe disease [27] [28] [29] [30] . However, it cannot be definitively determined if AMS is a result of a more severe disease or that neurological involvement, manifesting as AMS, is causing more severe features of COVID-19.

Older age, obesity, and being African American are all associated with poor health outcomes in COVID-19 patients [19, [31] [32] [33] [34] . The prevalence of obese patients in our study was 57% which is higher than Louisiana's average (35%) [35] . It should be acknowledged that the AMS cohort has a significantly older average age. However, when adjusted for age, AMS remained more associated with poor health outcomes , Fig 2. Notably, patients with AMS were less likely to be African American or have obesity, which strengthens the argument that AMS may be an independent risk factor for poor health outcomes in COVID-19 patients. But we were unable to explain the reason why.

There are many established etiologies of AMS, including neurologic, toxicologic, trauma, psychiatric, and infectious [34] . Neuropsychiatric comorbidities could predispose patients to develop AMS. In our cohort, there was no significant difference in the prevalence of neuropsychiatric comorbidities between patients with and without AMS. Additionally, AMS was remained associated with poor health outcomes when the analysis was adjusted for neuropsychiatric comorbidities, Fig 2. Dehydration is also associated with developing AMS, especially in elderly patients [36] . Diarrhea and vomiting are possible causes of dehydration, and there was no significant difference in the prevalence of these symptoms between the study groups. Additionally, AMS secondary to hospital-induced delirium can be ruled out, since all these patients presented with AMS at admission.

Further studies are needed to determine if presenting with only AMS is also associated with poor health outcomes, and why they are presented less in obese and African American patients, which may further strengthen the argument that it should be considered an independent risk factor for poor health outcomes. Limiting data analysis to data upon admission is a potential limitation, which makes it prone to missing data such as CT-scans, MRI, and CSF analysis, which are vital in identifying brain injury and signs of neurological invasion of SAR-CoV-2.

Influenza revisited

Novel Coronavirus Disease

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

COVID-19 and liver dysfunction: A systematic review and meta-analysis of retrospective studies

Cardiac Injury and COVID-19: A Systematic Review and Meta-Analysis

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2020

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Research Electronic Data Capture (REDCap)

Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19

Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Obesity and malnutrition similarly alter the reninangiotensin system and inflammation in mice and human adipose

but not low, exercise volume shifts the balance of reninangiotensin system toward ACE2/Mas receptor axis in skeletal muscle in obese rats

Comparative Expression of Renin-Angiotensin Pathway Proteins in Visceral Versus Subcutaneous Fat

Obesity as a predictor for a poor prognosis of COVID-19: A systematic review

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review

Neurological Manifestations of COVID-19: A systematic review and current update

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clinical Infectious Diseases 2020

The effect of cognitive impairment on the accuracy of the presenting complaint and discharge instruction comprehension in older emergency department patients

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

C-reactive protein levels in the early stage of COVID-19

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV

Severe outcomes among patients with coronavirus disease 2019 (COVID-19)

African Americans Struggle With the Current COVID-19

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Adult Obesity Prevalence Maps

Altered mental status in older patients in the emergency department